Equities

Allergy Therapeutics PLC

AGY:LSE

Allergy Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)5.10
  • Today's Change-0.10 / -1.92%
  • Shares traded620.23k
  • 1 Year change183.33%
  • Beta1.9163
Data delayed at least 20 minutes, as of Nov 22 2024 15:39 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Allergy Therapeutics PLC had revenues fall -7.36% from 59.59m to 55.20m, though the company grew net income from a loss of 43.07m to a smaller loss of 40.22m.
Gross margin53.87%
Net profit margin-72.86%
Operating margin-63.87%
Return on assets-61.12%
Return on equity-1,392.76%
Return on investment-86.97%
More ▼

Cash flow in GBPView more

In 2024, cash reserves at Allergy Therapeutics PLC fell by 1.93m. Cash Flow from Financing totalled 31.43m or 56.94% of revenues. In addition the company used 32.14m for operations while cash used for investing totalled 1.20m.
Cash flow per share-0.0089
Price/Cash flow per share--
Book value per share0.0008
Tangible book value per share-0.0002
More ▼

Balance sheet in GBPView more

Allergy Therapeutics PLC has a Debt to Total Capital ratio of 89.31%, a lower figure than the previous year's 1,654.69%.
Current ratio1.63
Quick ratio1.01
Total debt/total equity8.35
Total debt/total capital0.8931
More ▼

Growth rates in GBP

Year on year, growth in earnings per share excluding extraordinary items increased 63.69%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		63.47
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.